<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/484048</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Biochemistry</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genetic, structural, and functional analysis of mutations causing methylmalonyl-CoA epimerase deficiency</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Heuberger</surname><given-names>Kathrin</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x2021;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bailey</surname><given-names>Henry J.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">&#x2021;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Burda</surname><given-names>Patricie</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chaikuad</surname><given-names>Apirat</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Krysztofinska</surname><given-names>Ewelina</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Suormala</surname><given-names>Terttu</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>B&#x00FC;rer</surname><given-names>C&#x00E9;line</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lutz</surname><given-names>Seraina</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fowler</surname><given-names>Brain</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Froese</surname><given-names>D. Sean</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yue</surname><given-names>Wyatt W.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>

<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Baumgartner</surname><given-names>Matthias R.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>

<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Division of Metabolism and Children&#x2019;s Research Center, University Children&#x2019;s Hospital</institution>, CH-8032 Zurich, <country>Switzerland</country></aff>
<aff id="a2"><label>2</label><institution>Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford</institution>, UK OX3 7DQ</aff>
<aff id="a3"><label>3</label><institution>Present address: Institute of Pharmaceutical Chemistry &#x0026; Structural Genomics Consortium, BMLS, Goethe-University Frankfurt</institution>, 60438 Frankfurt, <country>Germany</country></aff>
<aff id="a4"><label>4</label><institution>Present address: Astex Pharmaceuticals</institution>, 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, <country>UK</country></aff>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>&#x2021;</label><p>equal contribution</p></fn>
<corresp id="cor1"><label>&#x002A;</label>Corresponding authors: Wyatt W. Yue and Matthias R. Baumgartner</corresp>
<fn id="n2" fn-type="equal"><p>Author contributions - D.S.F., B.F., M.R.B. and W.W.Y conceived of the project. D.S.F., P.B. and W.W.Y. designed the research. P.B., D.S.F. and W.W.Y. analysed the results. D.S.F. performed the size exclusion chromatography. K.H. performed the Western blots and [<sup>14</sup>C]-propionyl-CoA enzymatic assay. H.J.B. performed biophysical characterization of MCEE variants. C.B. sequenced the patients and identified the mutations. S.L. and T.S. performed the propionic acid incorporation assay. D.S.F., E.K. and H.J.B. produced the recombinant proteins. A.C. and H.J.B. solved the crystal structures. D.S.F. and W.W.Y. wrote the paper with contributions from other authors</p></fn>
</author-notes>
<pub-date pub-type="epub">
<year>2018</year>
</pub-date>
<elocation-id>484048</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>11</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="484048.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>Human methylmalonyl-CoA epimerase (<italic>MCEE</italic>) catalyzes the interconversion of D-methylmalonyl-CoA and L-methylmalonyl-CoA in propionate catabolism. Autosomal recessive mutations in <italic>MCEE</italic> reportedly cause methylmalonic aciduria (MMAuria) in eleven patients. We investigated a cohort of 150 individuals suffering from MMAuria of unknown origin, identifying ten new patients with mutations in <italic>MCEE</italic>. Nine patients were homozygous for the known nonsense mutation p.Arg47&#x002A; (c.139C&#x003E;T), and one for the novel missense mutation p.Ile53Arg (c.158T&#x003E;G). To understand better the molecular basis of MCEE deficiency, we mapped p.Ile53Arg, and two previously described patient mutations p.Lys60Gln and p.Arg143Cys, onto our 1.8 &#x00C5; structure of wild-type (wt) human MCEE. This revealed potential dimeric assembly disruption by p.Ile53Arg, but no clear defects from p.Lys60Gln or p.Arg143Cys. Functional analysis of MCEE-Ile53Arg expressed in a bacterial recombinant system as well as patient-derived fibroblasts revealed nearly undetectable soluble protein levels, defective globular protein behavior, and using a newly developed assay, lack of enzymatic activity - consistent with misfolded protein. By contrast, soluble protein levels, unfolding characteristics and activity of MCEE-Lys60Gln were comparable to wt, leaving unclear how this mutation may cause disease. MCEE-Arg143Cys was detectable at comparable levels to wt MCEE, but had slightly altered unfolding kinetics and greatly reduced activity. We solved the structure of MCEE-Arg143Cys to 1.9 &#x00C5; and found significant disruption of two important loop structures, potentially impacting surface features as well as the active-site pocket. These studies reveal ten new patients with MCEE deficiency and rationalize misfolding and loss of activity as molecular defects in MCEE-type MMAuria.</p>
</abstract>
<counts>
<page-count count="21"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Propionyl-CoA is the common degradation product from branched-chain amino acids, odd-chain fatty acids, and the side chain of cholesterol. The propionate catabolic pathway serves to funnel propionyl-CoA into the tricarboxylic acid (TCA) cycle for use as cellular energy sources through oxidative phosphorylation. Located at the centre of this pathway, methylmalonyl CoA epimerase (MCEE) catalyzes the epimerization of D-methylmalonyl-CoA, generated from propionyl-CoA by propionyl-CoA carboxylase (PCC), to form L-methylmalonyl-CoA, subsequently converted into succinyl-CoA by methylmalonyl-CoA mutase (MUT) for entry into the TCA cycle.</p>
<p>Isolated methylmalonic aciduria (MMAuria), an inborn error of organic acid metabolism, is typically caused by deficiency of MUT or by a defect in the transport or processing of its organometallic cofactor, adenosylcobalamin. However, mutations in the human <italic>MCEE</italic> gene (OMIM #251120) have been identified in eleven cases of atypical MMAuria (<xref rid="c1" ref-type="bibr">1</xref>-<xref rid="c6" ref-type="bibr">6</xref>). For two patients, coincidental mutations in the <italic>SPR</italic> gene causing sepiapterin reductase deficiency sufficiently explained their clinical symptoms (<xref rid="c2" ref-type="bibr">2</xref>,<xref rid="c4" ref-type="bibr">4</xref>), while two others have been described as asymptomatic (<xref rid="c3" ref-type="bibr">3</xref>), leaving the clinical importance of MCEE deficiency in doubt. The majority of patients with MCEE deficiency (seven including those with sepiapterin reductase deficiency) are homozygous for the stop-gain nonsense mutation c.139C&#x003E;T (p.Arg47&#x002A;)(<xref rid="c1" ref-type="bibr">1</xref>-<xref rid="c6" ref-type="bibr">6</xref>); the missense mutations p.Lys60Gln and p.Arg143Cys (<xref rid="c3" ref-type="bibr">3</xref>) and a splicing mutation (c.379-644A&#x003E;G) (<xref rid="c5" ref-type="bibr">5</xref>) have also been identified, but the functional relevance of these missense mutations remains unclear.</p>
<p>In the human genome, MCEE is one of six proteins belonging to the vicinal oxygen chelate (VOC) superfamily, which include also glyoxalase I (<italic>GLO1</italic> gene, GLOD1 protein), 4-hydroxyphenylpyruvic acid dioxygenase (<italic>HPD</italic>, GLOD3), 4-hydroxyphenylpyruvic acid dioxygenase-like (<italic>HPDL</italic>, GLOXD1), and glyoxalase domain-containing 4 (<italic>GLOD4</italic>) and 5 (<italic>GLOD5</italic>). VOC members are metalloenzymes highly divergent in sequence and biological functions, but universally share the use of the &#x03B2;&#x03B1;&#x03B2;&#x03B2;&#x03B2; structural motif (also known as the glyoxylase fold) to build a divalent metal-containing active site (<xref rid="c7" ref-type="bibr">7</xref>,<xref rid="c8" ref-type="bibr">8</xref>). VOC enzymes catalyze a range of chemical reactions including isomerization, epimerization, oxidative C-C bond cleavage and nucleophilic substitution (<xref rid="c9" ref-type="bibr">9</xref>). The active-site divalent metal is used to bind the reaction substrate, intermediates or transition states in a bidentate fashion (<xref rid="c8" ref-type="bibr">8</xref>). To date, only structures from bacterial MCEE orthologues (<italic>Propionibacterium shermanii</italic> and <italic>Thermoanaerobacter tengcongensis</italic>) have been reported (<xref rid="c10" ref-type="bibr">10</xref>,<xref rid="c11" ref-type="bibr">11</xref>).</p>
<p>In this article, we conducted an in depth investigation of MCEE deficiency at the gene and protein levels. From a cohort of 150 patients with MMAuria of unknown etiology, we identified ten new patients with mutations on the <italic>MCEE</italic> gene including a novel missense mutation. We determined the crystal structure of human MCEE of the wild-type as well as p.Arg143Cys variant proteins. We further characterized protein expression and enzyme activity for the three known MCEE missense mutations associated with disease. Our study provides a molecular explanation for the biochemical defects associated with the missense mutations.</p>
</sec>
<sec id="s2">
<title>Results &#x0026; Discussion</title>
<sec id="s2a">
<title>Identification of ten new MCEE patients with methylmalonic aciduria</title>
<p>Thus far, 11 cases of MMAuria have been identified due to mutations in the <italic>MCEE</italic> gene (<xref rid="c1" ref-type="bibr">1</xref>-<xref rid="c6" ref-type="bibr">6</xref>). We screened fibroblast cell lines taken from 150 patients with mild but clear MMAuria who could not be assigned to a cobalamin class of defect. From this cohort, we identified ten patients from nine families with mutations in <italic>MCEE</italic> (<xref rid="tbl1" ref-type="table">Table 1</xref>). All patients are homozygous for their respective mutations, of which nine out of ten harbour the previously described c.139C&#x003E;T (p.Arg47&#x002A;) nonsense mutation. This remains by far the most common mutation identified in MCEE deficiency, with 16 out of 21 patients homozygous for this allele. One patient in our cohort harboured c.158T&#x003E;G (p.Ile53Arg), a novel missense mutation that is not found in the ExAC database (&#x003E;120,000 alleles) (<xref rid="c12" ref-type="bibr">12</xref>). We did not observe either c.178A&#x003C;C (p.Lys60Gln), previously found in one patient in the homozygous state, or c.427C&#x003E;T (p.Arg143Cys), previously found in two patients in the heterozygous state without an apparent second mutation (<xref rid="c3" ref-type="bibr">3</xref>).</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><p>List of ten newly identified MCEE patients with relevant genetic, biochemical and clinical data.</p></caption>
<graphic xlink:href="484048v1_tbl1.tif"/>
</table-wrap>
<p>In our cohort, disease onset ranged from 1 month old to 2.5 years of age, while from two patients we had no information. Clinical symptoms were variable but usually mild, and no patient was responsive to vitamin B<sub>12</sub> treatment. At least three patients presented following an intercurrent illness, while three presented with metabolic acidosis and/or hypoglycemia. In addition, elevated levels of other metabolites typical for a block in the propionate degradation pathway, such as 2-methylcitrate, propionylcarnitine and 3-hydroxypropionate, were documented in most patients. Investigation in patient fibroblasts revealed mildly decreased propionate incorporation (<xref rid="tbl1" ref-type="table">Table 1</xref>), which did not increase upon addition of hydroxocobalamin.</p>
</sec>
<sec id="s2b">
<title>Structural features of human MCEE</title>
<p>We performed structural biology studies to establish the molecular basis of disease-causing mutations on the human MCEE protein (hMCEE). As a first step, we determined the crystal structure of wild-type (wt) protein (hMCEE<sub>WT</sub>) to 1.8 &#x00C5; resolution (<xref rid="tbl2" ref-type="table">Table 2</xref>), as part of a wider effort that also generated crystal structures of three other human VOCs, namely hHPD (PDB: 3ISQ), hGLOD4 (PDB 3ZI1) and hGLOD5 (PDB 3ZW5). Most VOC members are structurally made up of four glyoxylase (GLOD) motifs of &#x03B2;&#x03B1;&#x03B2;&#x03B2;&#x03B2; topology. As exemplified in Supplemental Fig. S1, the human VOCs display versatility in the way that four GLOD motifs are assembled, at the gene or protein level, to give rise to a minimal functional unit harbouring two metal-binding active sites.</p>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2.</label>
<caption><title>Data collection and refinement statistics for the crystal structures.</title>
<p>Data from highest resolution shell shown in parenthesis.</p></caption>
<graphic xlink:href="484048v1_tbl2.tif"/>
</table-wrap>
<p>In the case of hMCEE, two &#x03B2;&#x03B1;&#x03B2;&#x03B2;&#x03B2; motifs pack side-by-side to form an 8-stranded sheet that completes the active site for one protomer (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>). Crystallographic (supplemental Fig. S1) and solution data (supplemental Fig. S2) show that hMCEE is dimeric, in agreement with bacterial orthologs (<xref rid="c10" ref-type="bibr">10</xref>,<xref rid="c11" ref-type="bibr">11</xref>). The VOC members are so called because a divalent metal per active site can bind the substrate, intermediates or transition states in a bidentate fashion (<xref rid="c8" ref-type="bibr">8</xref>). The divalent metal ion in hMCEE, observed as cobalt in our structure, is coordinated by three residues strictly conserved among VOCs: His50 (strand &#x03B2;1), His122 (strand &#x03B2;5), and Glu172 (strand &#x03B2;8) (<xref rid="fig1" ref-type="fig">Fig. 1B</xref>).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Structure of hMCEE (PDB ID:3RMU).</title>
<p><bold>A.</bold> Monomeric structure coloured by secondary structure, whereby &#x03B2;-strands are green, &#x03B1;-helices that are part of the GLOD motif are red, and regions that connect GLOD motifs are yellow. <bold>B.</bold> Active-site architecture showing the divalent metal and metal coordinating residues. Pink sphere: cobalt. <bold>C.</bold> On the hMCEE monomer, residues that are mutated in disease are labeled in orange, active-site residues are labeled in black. <bold>D.</bold> hMCEE physiological dimer with the second subunit represented as grey space fill. Mutations are labeled in orange and designated as belonging to chain (monomer) A or B.</p></caption>
<graphic xlink:href="484048v1_fig1.tif"/>
</fig>
</sec>
<sec id="s2c">
<title>Structural mapping of MCEE mutations</title>
<p>Both the reported p.Arg143Cys and newly identified p.Ile53Arg missense mutations are predicted by SIFT (Damaging, score: 0.00 &#x0026; 0.01) and PolyPhen2 (Probably damaging, score: 0.989 &#x0026; 1.00) to be deleterious. By contrast, the other previously reported mutation p.Lys60Gln was predicted to be not deleterious (SIFT: 0.12 tolerated, PolyPhen2: 0.04 benign). The most common mutation of MCEE, c.139C&#x003E;T, causes truncation of the protein at p.Arg47&#x002A;, within the first &#x03B2;-sheet (supplemental Fig. S3). Loss of almost the entire protein is therefore the likely cause of enzymatic dysfunction due to this mutation, assuming there is residual mRNA following nonsense-mediated decay.</p>
<p>By contrast, the molecular dysfunction due to the missense mutations is less clear (<xref rid="fig1" ref-type="fig">Fig. 1C</xref>). In our hMCEE structure, Ile53 is located at the dimeric interface, making hydrophobic contacts with Gly168 and Val169 from the loop region connecting strands &#x03B2;7 and &#x03B2;8 (loop<sub>&#x03B2;7-</sub> &#x03B2;8) of the other subunit in the dimer, (<xref rid="fig1" ref-type="fig">Fig. 1D</xref>). The amino acid (aa) position of Ile53 is highly conserved among MCEE orthologues (85&#x0025; occupied by Ile, n=150). An Ile-to-Arg at this position likely interferes with proper dimeric assembly, and is predicted by FoldX (<xref rid="c13" ref-type="bibr">13</xref>) to have severely reduced stability (&#x0394;&#x0394;G 9.53 kcal/mol). By contrast, Lys60 and Arg143 occupy amino acid positions that are more variable. Position 60 is only occupied by lysine in 15&#x0025; of MCEE homologs while position 143 is 60&#x0025; occupied by arginine. Both residues are surface exposed and not directly involved in the dimeric interface and active-sites of both subunits (<xref rid="fig1" ref-type="fig">Fig. 1D</xref>), consistent with a FoldX prediction of no effect for p.Lys60Gln (&#x0394;&#x0394;G 0.3 kcal/mol), and moderately reduced stability for p.Arg143Cys (&#x0394;&#x0394;G 2.26 kcal/mol).</p>
</sec>
<sec id="s2d">
<title>Characterization of MCEE mutations in recombinant and patient cells</title>
<p>To validate our structural interpretation of mutations, we performed expression studies in <italic>E. coli</italic> and human cells. When expressed in <italic>E. coli</italic> (<xref rid="fig2" ref-type="fig">Fig. 2A</xref>), hMCEE wt, p.Lys60Gln and p.Arg143Cys proteins were highly soluble, while the p.Ile53Arg variant showed a massive decrease in protein solubility, consistent with a poorly folded protein. All wt and variant hMCEE molecules eluted at similar volumes by size exclusion chromatography (supplemental Fig. S4). Thermal unfolding (<xref rid="fig2" ref-type="fig">Fig. 2B</xref>) of purified hMCEE p.Ile53Arg by nano-differential scanning fluorimetry revealed a melting curve of multiple transitions, indicative of heterogenous protein states. By contrast, purified wt and p.Lys60Gln proteins showed globular protein behaviour reflected by a cooperative sigmoidal melting pattern, indicating a single unfolding/folding transition. p.Arg143Cys also behaved similarly to wt and p.Lys60Gln, however late stage unfolding/folding intermediates deviate from sigmoidal melting. Together our data indicate reduced thermostability for the p.Ile53Arg variant protein and a potential slight alteration in that of p.Arg143Cys.</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Characterization of recombinant hMCEE wt and variant proteins.</title>
<p><bold>A.</bold> SDS-PAGE analysis of hMCEE protein expression (from cell lysate: Total Lysis; and centrifuged supernatant fractions: Soluble) and solubility (from eluant fractions of affinity purification); <bold>B.</bold> nanoDSF melting curve plot of normalized light scattering intensity against temperature.</p></caption>
<graphic xlink:href="484048v1_fig2.tif"/>
</fig>
<p>These results were validated by over-expression of hMCEE in patient fibroblasts homozygous for the <italic>MCEE</italic> null mutation (c.139C&#x003E;T; p.Arg47&#x002A;). For this experiment, flag-tagged wt and mutant hMCEE proteins were over-expressed with visualization of the flag-tag by Western blot analysis (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>A</italic>). Expression of each construct performed at least 3 times revealed wt protein to be well expressed, while hMCEE containing p.Lys60Gln and p.Arg143Cys were detectable at only slightly lower levels (63 &#x00B1; 17&#x0025; and 74 &#x00B1; 26&#x0025; of wt, respectively) (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>B</italic>). However, hMCEE containing p.Ile53Arg had very low levels of detectable protein (6 &#x00B1; 1&#x0025; of wt), similar to empty vector (4 &#x00B1; 2&#x0025; of wt) (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>B</italic>). Thus, consistent with recombinant studies, it appears that p.Ile53Arg causes an inability to fold correctly.</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Over-expression of hMCEE-flag in human fibroblasts.</title>
<p><bold>A.</bold> Representative Western blots depicting detection of wild-type (wt) or mutant hMCEE-flag following over-expression in patient fibroblasts deficient for MCEE enzyme. Vector without insert was used as a control (e.v.). Loading was controlled by detection of endogenous &#x03B2;-actin. Numbers on the left correspond to molecular weights (kDa). Approximate expected molecular weights, hMCEE-flag: 18 kDa; &#x03B2;-actin: 42 kDa. <bold>B.</bold> Bar-graph depicting mean and standard deviation of Western blot results performed in 3 independent experiments.</p></caption>
<graphic xlink:href="484048v1_fig3.tif"/>
</fig>
</sec>
<sec id="s2e">
<title>Structure of human MCEE p.Arg143Cys variant</title>
<p>We determined the crystal structure of the p.Arg143Cys variant protein (hMCEE<sub>R143C</sub>) to 1.9 &#x00C5; resolution (<xref rid="tbl2" ref-type="table">Table 2</xref>), to directly inspect the atomic environment of the substitution (<xref rid="fig4" ref-type="fig">Fig. 4</xref>). While hMCEE<sub>R143C</sub> superimposes well overall with hMCEE<sub>WT</sub> (C&#x03B1;-RMSD 0.278 &#x00C5;), significant main-chain displacement was clearly observed in the loop region connecting helix &#x03B1;3 and &#x03B2;6 (loop<sub>&#x03B1;3-&#x03B2;6</sub>) that harbours the site of mutation at aa 143, as well as the nearby loop<sub>&#x03B2;7-&#x03B2;8</sub> (<xref rid="fig4" ref-type="fig">Fig. 4</xref>, inset). These loop regions connect several &#x03B2;-strands that make up the protomer active site. In the hMCEE<sub>R143C</sub> structure, the substituted Cys143 residue generated more mobility and disorder within the loop<sub>&#x03B1;3-&#x03B2;6</sub>. As a result, the main-chain atoms of aa 142-146 are displaced by &#x223C;2.5-4.7 &#x00C5; compared to hMCEE<sub>WT</sub>. The increased mobility in loop<sub>&#x03B1;3-&#x03B2;6</sub> impacts on the nearby loop<sub>&#x03B2;7-&#x03B2;8</sub> that packs against it, resulting in 2.0-4.8 &#x00C5; main-chain displacement at the first half of loop<sub>&#x03B2;7-&#x03B2;8</sub> (aa 164-167). The second half of loop<sub>&#x03B2;7-&#x03B2;8</sub>, involved in the aforementioned dimeric interface, was not affected by any displacement. Together, these local structural changes have the potential to impact on the surface features of the homodimer, as well as the active site pocket.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Structure of hMCEE p.Arg143Cys variant.</title>
<p>Structural superposition of hMCEE homodimer from hMCEE<sub>WT</sub> (yellow) and hMCEE<sub>R143</sub> (cyan) proteins. <bold><italic>Inset.</italic></bold> Magnified view of the local atomic environment surrounding the Arg143/Cys143 site, where amino acid side-chains are shown as thin lines.</p></caption>
<graphic xlink:href="484048v1_fig4.tif"/>
</fig>
</sec>
<sec id="s2f">
<title>Biochemical characterization of MCEE mutations</title>
<p>We developed a radioactive HPLC-based assay to assess MCEE activity of wt and variants. This assay follows the production and separation of [<sup>14</sup>C]-methylmalonic acid and [<sup>14</sup>C]-succinic acid from [<sup>14</sup>C]-propionic acid following addition of [<sup>14</sup>C]-propionyl-CoA to fibroblast cell lysates, as depicted in <xref rid="fig5" ref-type="fig">Fig. 5</xref><italic>A</italic>. Using UV detection, we were able to detect separated propionic acid, methylmalonic acid and succinic acid following HPLC analysis (supplemental Fig. S5). In cell lysates from control fibroblasts, we identified high levels of [<sup>14</sup>C]- methylmalonic acid but only very little [<sup>14</sup>C]-succinic acid (<xref rid="fig5" ref-type="fig">Fig. 5</xref><italic>B</italic>; supplemental Fig. S6<italic>A</italic>). To determine if MUT or MCEE was rate-limiting for succinate production, we expressed each individually, or together (<xref rid="fig5" ref-type="fig">Fig. 5</xref><italic>B</italic>; supplemental Fig. S6<italic>B</italic>-<italic>C</italic>). While over-expressed MUT-alone only marginally increased detectable [<sup>14</sup>C]-succinic acid, MCEE expression alone, and especially co-expression with MUT, provided a marked increase in [<sup>14</sup>C]-succinic acid (<xref rid="fig5" ref-type="fig">Fig. 5</xref><italic>B</italic>; supplemental Fig. 6<italic>D</italic>). Therefore, MCEE appears to be the rate-limiting step in this pathway. This same basic pattern could be seen in MCEE null fibroblasts (<xref rid="fig5" ref-type="fig">Fig. 5</xref><italic>C</italic>).</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Biochemical analysis of hMCEE disease associated mutations.</title>
<p><bold>A.</bold> Schematic depiction of the cellular pathway leading from propionyl-CoA to succinyl-CoA and the enzymes involved in this process. <bold>B and C.</bold> Bar-graph showing the amount of methylmalonic acid (MMA) and succinate following over-expression of empty vector (e.v.), methylmalonyl-CoA mutase (MUT) alone, MCEE alone, or both MCEE and MUT in control fibroblasts (<bold>B</bold>) and patient fibroblasts deficient in MCEE (<bold>C</bold>). <bold>D.</bold> Bar graph depicting production of MMA and succinate following over-expression of wild-type (wt) and mutant MCEE in the presence of over-expressed MUT in MCEE patient fibroblasts. Results shown represent the mean and standard deviation of 3 independent experiments.</p></caption>
<graphic xlink:href="484048v1_fig5.tif"/>
</fig>
<p>We further examined the effect of the mutant MCEE proteins in the presence of over-expressed MUT in MCEE null fibroblast lysates (<xref rid="fig5" ref-type="fig">Fig. 5</xref><italic>D</italic>). Over-expression of MCEE harbouring p.Ile53Arg resulted in very little detectable [<sup>14</sup>C]-succinate. This is consistent with an inability to convert D-methylmalonyl-CoA to L-methylmalonyl-CoA due to a lack of correctly folded protein, as was demonstrated by Western blot analysis. By contrast, over-expressed MCEE harbouring p.Lys60Gln produced similar levels of detectable succinate as wt protein. Finally, despite being well expressed, MCEE harbouring p.Arg143Cys had markedly reduced [<sup>14</sup>C]-succinic acid production, agreeing with the significantly altered local environment in the hMCEE<sub>R143C</sub> structure. This conformational change could impair enzymatic activity of p.Arg143Cys either by direct structural interference with the active site, or indirectly e.g. via loss of essential interactions with other proteins in the succinyl-CoA production pathway.</p>
</sec>
</sec>
<sec id="s3">
<title>Conclusions</title>
<p>The identification of an additional ten patients with MCEE deficiency adds more information toward the debate of whether deficiency of this protein does indeed cause disease and not just elevated methylmalonic acid levels, and confirms that complete MCEE deficiency, despite low penetrance, may lead to an acute clinical phenotype with metabolic crisis resembling classical organic acidurias, similar to e.g. 3-methylcrotonyl-CoA carboxylase deficiency (<xref rid="c14" ref-type="bibr">14</xref>). Our combined structural, biophysical and enzymatic assessment of MCEE defects confirm the importance of this protein within the propionate degradation pathway. While protein-destabilizing mutations (e.g. p.Ile53Arg) explains enzymatic defects more readily, mutations away from the active-site (e.g. p.Arg143Cys) could still cause a loss of activity, although the underlying mechanism needs further clarification. In regards to p.Lys60Gln, however, we could identify no defect conferred to the protein, leaving the molecular mechanism and its potential to cause disease in doubt.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material>
<media xlink:href="supplements/484048_file02.docx" />
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by the Rare Disease Initiative Zurich, a Clinical Research Priority Program from the University of Zurich (to D. S. F. and M. R. B.) and the Swiss National Science Foundation [SNSF 31003A_175779] (to M.R.B.). The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, MSD, Merck KGaA, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, S&#x00E3;o Paulo Research Foundation-FAPESP, Takeda and Wellcome Trust [106169/ZZ14/Z]. We thank Dr. Holger Blessing (Universit&#x00E4;tsklinikum Erlangen, Germany), Dr. Ernst Christensen (Rigshospitalet, Copenhagen, Denmark), Dr. Andrew Morris (Alder Hey, Liverpool, UK), Dr. Murray Bain (St. George&#x2019;s Hospital Medical School, London, UK), Dr. Mike Champion (St. Thomas&#x2019; Hospital, London, UK), Dr. W.C.G. Overweg-Plandsoen (Academisch Ziekenhuis bij de Universiteit van Amsterdam, Netherlands), Dr. Dorothea M&#x00F6;slinger (Universit&#x00E4;tsklinik f&#x00FC;r Kinder und Jugendliche, Wien, Austria), Dr. Anne-Margret Wingen (Universit&#x00E4;tsklinikum Essen, Germany) and Dr. Ina Knerr (University Children&#x2019;s Hospital, Dublin, Ireland) for sending patient material and data. We thank the Diamond Light Source for access to the beamlines and Carmen Diez-Fernandez for critical comments on the manuscript.</p>
</ack>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Reagents</title>
<p>Unless otherwise noted, all compounds were obtained from Sigma-Aldrich (Buchs SG, Switzerland) and were reagent grade or better.</p>
</sec>
<sec id="s4b">
<title>Purification, crystallization and structure determination of hMCEE</title>
<p>hMCEE was cloned, expressed and purified as previously described (<xref rid="c15" ref-type="bibr">15</xref>). Briefly, wt and variant proteins were expressed in <italic>Escherichia coli</italic> BL21(DE3)R3-Rosetta cells from 3-6 L of Terrific Broth culture. Cell pellets were lysed by high pressure homogenizer and centrifuged at 35,000 x<italic>g</italic>. The clarified cell extract was incubated with 2.5 ml of Ni-NTA resin pre-equilibrated with lysis buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 10 mM Imidazole, 5&#x0025; Glycerol, 0.5 mM TCEP). The column was washed with 100 ml Binding Buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5&#x0025; glycerol, 10 mM Imidazole, 0.5 mM TCEP), 50 ml Wash Buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5&#x0025; glycerol, 40 mM Imidazole, 0.5 mM TCEP) and eluted with 15 ml of Elution Buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5&#x0025; glycerol, 250 mM Imidazole, 0.5 mM TCEP). The eluant fractions were concentrated to 5 ml and applied to a Superdex 200 16/60 column pre-equilibrated in GF Buffer (10 mM HEPES pH 7.5, 500 mM NaCl, 0.5 mM TCEP, 5&#x0025; glycerol). Eluted protein fractions were incubated with 1:20 mol:mol TEV protease overnight at 4&#x00B0;C. The next day sample was passed through 0.5 ml Ni-NTA pre-equilibrated with GF Buffer and washed 1 ml of GF Buffer. Flow-through and wash were pooled and concentrated to 10-15 mg/ml.</p>
<p>Crystals of hMCEE<sub>WT</sub> were grown by vapour diffusion in sitting drop at 20&#x00B0;C. A sitting drop consisting of 75 nl protein and 75 nl well solution was equilibrated against well solution containing 30&#x0025; (v/v) low molecular weight PEG smear (<xref rid="c16" ref-type="bibr">16</xref>) and 0.1 M Tris pH 8.5. Crystals were mounted in the presence of 25&#x0025; (v/v) ethylene glycol and flash-cooled in liquid nitrogen. Crystals of hMCEE<sub>R143C</sub> were grown by vapour diffusion in sitting drop at 20&#x00B0;C. A sitting drop consisting of 50 nl protein and 100 nl well solution was equilibrated against well solution containing 20&#x0025; PEG4000, 10&#x0025; 2-propanol and 0.1M HEPES pH 7.5. Crystals were mounted in the presence of 25&#x0025; (v/v) ethylene glycol and flash-cooled in liquid nitrogen. Crystallization and diffraction data are given in <xref rid="tbl2" ref-type="table">Table 2</xref>. The structure of hMCEE<sub>WT</sub> was solved by molecular replacement using PHASER (<xref rid="c17" ref-type="bibr">17</xref>), with <italic>P. shermanii</italic> MCEE structure (PDB 1JC5) as search model. The structure of hMCEE<sub>R143C</sub> was solved by molecular replacement with hMCEE wt as search model. Iterative cycles of refinement and manual model building using COOT (<xref rid="c18" ref-type="bibr">18</xref>), REFMAC5 (<xref rid="c19" ref-type="bibr">19</xref>) and phenix.refine (<xref rid="c20" ref-type="bibr">20</xref>) (PMID: 22505256).</p>
</sec>
<sec id="s4c">
<title>Size Exclusion Chromatography</title>
<p>Size exclusion chromatography was performed as described in (<xref rid="c21" ref-type="bibr">21</xref>).</p>
</sec>
<sec id="s4d">
<title>Nano-Differential Scanning Fluorimetry</title>
<p>Melting curves for the wt protein and mutants were obtained via detection of changes in light scattering using the Prometheus NT.48. Protein concentration was kept at 100 &#x00B5;M in 50 mM HEPES pH 7.5, 500 mM NaCl, 0.5 mM TCEP, 5&#x0025; glycerol and a melt gradient of 1 degree per minute 20&#x00B0;C to 95&#x00B0;C was used.</p>
</sec>
<sec id="s4e">
<title>Patient Characterization (genotyping, propionate incorporation)</title>
<p>Skin fibroblasts were taken from patients with biochemical and clinical evidence of methylmalonic aciduria, referred to our institution for diagnostic purposes. The study has been approved by the ethics commission of the Canton of Zurich, Switzerland (application no. 2014-0211). Genomic DNA and RNA extraction, as well as sequencing and propionate incorporation were performed as previously described (<xref rid="c21" ref-type="bibr">21</xref>). The nomenclature of the mutations is based on the cDNA sequence NM_032601.3. Nucleotide numbering uses &#x002B;1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1.</p>
</sec>
<sec id="s4f">
<title>Transfection, Immunoblotting and Enzymatic Assay</title>
<p>A DNA fragment encompassing the entire coding sequence of wild-type MCEE was cloned into pcDNA3-CT10HF-LIC using LIC cloning. The sequence was as given by NM_032601.3, except for c.311T&#x003E;G (p.Lue104Arg), whereby c.311G is the more common allele, (<xref rid="c12" ref-type="bibr">12</xref>). Site-directed mutagenesis was carried out on this construct using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) as described in the manufacturer&#x2019;s instructions, using forward and reverse primers (Microsynth, Balgach, Switzerland) and confirmed by Sanger sequencing. Control (BJ, CRL-2522, ATCC) or patient (carrying homozygous MCEE mutation c.139C&#x003E;T, p.Arg47&#x002A;) fibroblasts were transiently transfected with 10 &#x00B5;g wild-type or mutant MCEE constructs, with or without 10 &#x00B5;g MUT in pTracer (<xref rid="c22" ref-type="bibr">22</xref>) for the enzymatic assay, using electroporation (<xref rid="c23" ref-type="bibr">23</xref>). Cells were grown in Dulbecco&#x2019;s Modified Eagle Medium (Gibco) supplemented with 10&#x0025; fetal bovine serum (Gibco) and antibiotics (GE Healthcare), as previously described (<xref rid="c24" ref-type="bibr">24</xref>) and harvested by trypsinization 48 hr after electroporation, washed twice with HBSS (Gibco) and either frozen at &#x2212;20&#x00B0;C or processed directly.</p>
<p>Western Blot analysis was performed on fresh or frozen cell pellets essentially as described in (<xref rid="c22" ref-type="bibr">22</xref>), with the exception that monoclonal anti-flagM2 (1:4,000; Sigma&#x2013;Aldrich) and anti-&#x03B2;-Actin (at 1:5,000; Sigma&#x2013;Aldrich) were used.</p>
<p>For the enzymatic assay, fresh or frozen cell pellet was lysed in buffer including 12 mM Tris-HCl, pH 8.0 and 1mM DTT with sonication twice at amplitude 1.5 for 15 seconds using the microprobe of an XL-2000 sonicator (Microson, Qsonica Newtown, CT). Following lysis, protein concentration was determined by the Lowry method. The incubation mixture contained 300-500 &#x00B5;g cell protein, reaction buffer (100 mM Tris-HCl, pH 8.0; 6 mM MgCl<sub>2</sub>; 3.15 mM ATP; 100 mM KCl; 3 mM DTT), 1 mM propionyl-CoA mix (1 mM propionyl-CoA and 7 &#x00B5;M [<sup>14</sup>C]-propionyl-CoA at 55 mCi/mmol, Anawa, Switzerland) and 50 uM adenosylcobalamin and reaction time was 60 minutes at 37&#x00B0;C. The reaction was stopped by adding 0.5M KOH, samples were then re-incubated for 15 minutes at 37&#x00B0;C to hydrolyze CoA derivatives, neutralized by adding 0.5 N perchloric acid (Merck), and spiked with 0.05&#x0025; succinic acid, 0.018&#x0025; methylmalonic acid and 0.018&#x0025; propionic acid in order to visualize peaks during HPLC separation. Samples were centrifuged to remove precipitate, and supernatant was injected into an Aminex HPX-87H Ion Exclusion column (300 &#x00D7; 7.8 mm2; H-form, 9 &#x03BC;m, Bio-Rad), and organic acids separated by elution with 0.5 mM H<sub>2</sub>SO<sub>4</sub> at 30&#x00B0;C using a flow rate of 0.4 ml/min. Retention times were 13-15 minutes for methylmalonic acid, 17-19 minutes for succinic acid, and 26-28 minutes for propionic acid (supplemental Fig. S5 and 6), visualized at 210 nm using a UV detector. Fractions covering the methylmalonic acid and succinic acid peaks were collected and [<sup>14</sup>C]-methylmalonic acid and [<sup>14</sup>C]-succinic acid quantified in a Tri-Carb C1 900TR scintillation spectrometer (PerkinElmer,Waltham, MA, USA) with OptiphaseHiSafe 2 counting cocktail (PerkinElmer).</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>[1]</label><mixed-citation publication-type="journal"><string-name><surname>Dobson</surname>, <given-names>C. M.</given-names></string-name>, <string-name><surname>Gradinger</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Longo</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Leclerc</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Lerner-Ellis</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Lemieux</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Belair</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Watkins</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Rosenblatt</surname>, <given-names>D. S.</given-names></string-name>, and <string-name><surname>Gravel</surname>, <given-names>R. A.</given-names></string-name> (<year>2006</year>) <article-title>Homozygous nonsense mutation in the MCEE gene and siRNA suppression of methylmalonyl-CoA epimerase expression: a novel cause of mild methylmalonic aciduria</article-title>. <source>Mol Genet Metab</source> <volume>88</volume>, <fpage>327</fpage>&#x2013;<lpage>333</lpage></mixed-citation></ref>
<ref id="c2"><label>[2]</label><mixed-citation publication-type="journal"><string-name><surname>Bikker</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Bakker</surname>, <given-names>H. D.</given-names></string-name>, <string-name><surname>Abeling</surname>, <given-names>N. G.</given-names></string-name>, <string-name><surname>Poll-The</surname>, <given-names>B. T.</given-names></string-name>, <string-name><surname>Kleijer</surname>, <given-names>W. J.</given-names></string-name>, <string-name><surname>Rosenblatt</surname>, <given-names>D. S.</given-names></string-name>, <string-name><surname>Waterham</surname>, <given-names>H. R.</given-names></string-name>, <string-name><surname>Wanders</surname>, <given-names>R. J.</given-names></string-name>, and <string-name><surname>Duran</surname>, <given-names>M.</given-names></string-name> (<year>2006</year>) <article-title>A homozygous nonsense mutation in the methylmalonyl-CoA epimerase gene (MCEE) results in mild methylmalonic aciduria</article-title>. <source>Hum Mutat</source> <volume>27</volume>, <fpage>640</fpage>&#x2013;<lpage>643</lpage></mixed-citation></ref>
<ref id="c3"><label>[3]</label><mixed-citation publication-type="journal"><string-name><surname>Gradinger</surname>, <given-names>A. B.</given-names></string-name>, <string-name><surname>Belair</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Worgan</surname>, <given-names>L. C.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>C. D.</given-names></string-name>, <string-name><surname>Lavallee</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Roquis</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Watkins</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>Rosenblatt</surname>, <given-names>D. S.</given-names></string-name> (<year>2007</year>) <article-title>Atypical methylmalonic aciduria: frequency of mutations in the methylmalonyl CoA epimerase gene (MCEE</article-title>). <source>Hum Mutat</source> <volume>28</volume>, <fpage>1045</fpage></mixed-citation></ref>
<ref id="c4"><label>[4]</label><mixed-citation publication-type="journal"><string-name><surname>Mazzuca</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Maubert</surname>, <given-names>M. A.</given-names></string-name>, <string-name><surname>Damaj</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Clot</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Cadoudal</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Dubourg</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Odent</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Benoit</surname>, <given-names>J. F.</given-names></string-name>, <string-name><surname>Bahi-Buisson</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Christa</surname>, <given-names>L.</given-names></string-name>, and <string-name><surname>de Lonlay</surname>, <given-names>p.</given-names></string-name> (<year>2015</year>) <article-title>Combined Sepiapterin Reductase and Methylmalonyl-CoA Epimerase Deficiency in a Second Patient: Cerebrospinal Fluid Polyunsaturated Fatty Acid Level and Follow-Up Under L-DOPA, 5-HTP and BH4 Trials</article-title>. <source>JIMD Rep</source> <volume>22</volume>, <fpage>47</fpage>&#x2013;<lpage>55</lpage></mixed-citation></ref>
<ref id="c5"><label>[5]</label><mixed-citation publication-type="journal"><string-name><surname>Waters</surname>, <given-names>p. J.</given-names></string-name>, <string-name><surname>Thuriot</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Clarke</surname>, <given-names>J. T.</given-names></string-name>, <string-name><surname>Gravel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Watkins</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Rosenblatt</surname>, <given-names>D. S.</given-names></string-name>, and <string-name><surname>Levesque</surname>, <given-names>S.</given-names></string-name> (<year>2016</year>) <article-title>Methylmalonyl-coA epimerase deficiency: A new case, with an acute metabolic presentation and an intronic splicing mutation in the MCEE gene</article-title>. <source>Mol Genet Metab Rep</source> <volume>9</volume>, <fpage>19</fpage>&#x2013;<lpage>24</lpage></mixed-citation></ref>
<ref id="c6"><label>[6]</label><mixed-citation publication-type="journal"><string-name><surname>Abily-Donval</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Torre</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Samson</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sudrie-Arnaud</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Acquaviva</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Guerrot</surname>, <given-names>A. M.</given-names></string-name>, <string-name><surname>Benoist</surname>, <given-names>J. F.</given-names></string-name>, <string-name><surname>Marret</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bekri</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Tebani</surname>, <given-names>A.</given-names></string-name> (<year>2017</year>) <article-title>Methylmalonyl-CoA Epimerase Deficiency Mimicking Propionic Aciduria</article-title>. <source>Int J Mol Sci</source> <volume>18</volume></mixed-citation></ref>
<ref id="c7"><label>[7]</label><mixed-citation publication-type="journal"><string-name><surname>Armstrong</surname>, <given-names>R. N.</given-names></string-name> (<year>2000</year>) <article-title>Mechanistic diversity in a metalloenzyme superfamily</article-title>. <source>Biochemistry</source> <volume>39</volume>, <fpage>13625</fpage>&#x2013;<lpage>13632</lpage></mixed-citation></ref>
<ref id="c8"><label>[8]</label><mixed-citation publication-type="journal"><string-name><surname>He</surname>, <given-names>p.</given-names></string-name>, and <string-name><surname>Moran</surname>, <given-names>G. R.</given-names></string-name> (<year>2011</year>) <article-title>Structural and mechanistic comparisons of the metal-binding members of the vicinal oxygen chelate (VOC) superfamily</article-title>. <source>J Inorg Biochem</source> <volume>105</volume>, <fpage>1259</fpage>&#x2013;<lpage>1272</lpage></mixed-citation></ref>
<ref id="c9"><label>[9]</label><mixed-citation publication-type="journal"><string-name><surname>Meng</surname>, <given-names>E. C.</given-names></string-name>, and <string-name><surname>Babbitt</surname>, <given-names>p. C.</given-names></string-name> (<year>2011</year>) <article-title>Topological variation in the evolution of new reactions in functionally diverse enzyme superfamilies</article-title>. <source>Curr Opin Struct Biol</source> <volume>21</volume>, <fpage>391</fpage>&#x2013;<lpage>397</lpage></mixed-citation></ref>
<ref id="c10"><label>[10]</label><mixed-citation publication-type="journal"><string-name><surname>McCarthy</surname>, <given-names>A. A.</given-names></string-name>, <string-name><surname>Baker</surname>, <given-names>H. M.</given-names></string-name>, <string-name><surname>Shewry</surname>, <given-names>S. C.</given-names></string-name>, <string-name><surname>Patchett</surname>, <given-names>M. L.</given-names></string-name>, and <string-name><surname>Baker</surname>, <given-names>E. N.</given-names></string-name> (<year>2001</year>) <article-title>Crystal structure of methylmalonyl-coenzyme A epimerase from P. shermanii: a novel enzymatic function on an ancient metal binding scaffold</article-title>. <source>Structure</source> <volume>9</volume>, <fpage>637</fpage>&#x2013;<lpage>646</lpage></mixed-citation></ref>
<ref id="c11"><label>[11]</label><mixed-citation publication-type="journal"><string-name><surname>Shi</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>p.</given-names></string-name>, <string-name><surname>Yan</surname>, <given-names>X. X.</given-names></string-name>, and <string-name><surname>Liang</surname>, <given-names>D. C.</given-names></string-name> (<year>2009</year>) <article-title>Crystal structure of a putative methylmalonyl-coenzyme A epimerase from Thermoanaerobacter tengcongensis at 2.0 A resolution</article-title>. <source>Proteins</source> <volume>77</volume>, <fpage>994</fpage>&#x2013;<lpage>999</lpage></mixed-citation></ref>
<ref id="c12"><label>[12]</label><mixed-citation publication-type="journal"><string-name><surname>Lek</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Karczewski</surname>, <given-names>K. J.</given-names></string-name>, <string-name><surname>Minikel</surname>, <given-names>E. V.</given-names></string-name>, <string-name><surname>Samocha</surname>, <given-names>K. E.</given-names></string-name>, <string-name><surname>Banks</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Fennell</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>O&#x2019;Donnell-Luria</surname>, <given-names>A. H.</given-names></string-name>, <string-name><surname>Ware</surname>, <given-names>J. S.</given-names></string-name>, <string-name><surname>Hill</surname>, <given-names>A. J.</given-names></string-name>, <string-name><surname>Cummings</surname>, <given-names>B. B.</given-names></string-name>, <string-name><surname>Tukiainen</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Birnbaum</surname>, <given-names>D. P.</given-names></string-name>, <string-name><surname>Kosmicki</surname>, <given-names>J. A.</given-names></string-name>, <string-name><surname>Duncan</surname>, <given-names>L. E.</given-names></string-name>, <string-name><surname>Estrada</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Zou</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Pierce-Hoffman</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Berghout</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cooper</surname>, <given-names>D. N.</given-names></string-name>, <string-name><surname>Deflaux</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>DePristo</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Do</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Flannick</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Fromer</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Gauthier</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Goldstein</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Gupta</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Howrigan</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Kiezun</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kurki</surname>, <given-names>M. I.</given-names></string-name>, <string-name><surname>Moonshine</surname>, <given-names>A. L.</given-names></string-name>, <string-name><surname>Natarajan</surname>, <given-names>p.</given-names></string-name>, <string-name><surname>Orozco</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Peloso</surname>, <given-names>G. M.</given-names></string-name>, <string-name><surname>Poplin</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Rivas</surname>, <given-names>M. A.</given-names></string-name>, <string-name><surname>Ruano-Rubio</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Rose</surname>, <given-names>S. A.</given-names></string-name>, <string-name><surname>Ruderfer</surname>, <given-names>D. M.</given-names></string-name>, <string-name><surname>Shakir</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Stenson</surname>, <given-names>p. D.</given-names></string-name>, <string-name><surname>Stevens</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Thomas</surname>, <given-names>B. P.</given-names></string-name>, <string-name><surname>Tiao</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Tusie-Luna</surname>, <given-names>M. T.</given-names></string-name>, <string-name><surname>Weisburd</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Won</surname>, <given-names>H. H.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Altshuler</surname>, <given-names>D. M.</given-names></string-name>, <string-name><surname>Ardissino</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Boehnke</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Danesh</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Donnelly</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Elosua</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Florez</surname>, <given-names>J. C.</given-names></string-name>, <string-name><surname>Gabriel</surname>, <given-names>S. B.</given-names></string-name>, <string-name><surname>Getz</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Glatt</surname>, <given-names>S. J.</given-names></string-name>, <string-name><surname>Hultman</surname>, <given-names>C. M.</given-names></string-name>, <string-name><surname>Kathiresan</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Laakso</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>McCarroll</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>McCarthy</surname>, <given-names>M. I.</given-names></string-name>, <string-name><surname>McGovern</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>McPherson</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Neale</surname>, <given-names>B. M.</given-names></string-name>, <string-name><surname>Palotie</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Purcell</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Saleheen</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Scharf</surname>, <given-names>J. M.</given-names></string-name>, <string-name><surname>Sklar</surname>, <given-names>p.</given-names></string-name>, <string-name><surname>Sullivan</surname>, <given-names>p. F.</given-names></string-name>, <string-name><surname>Tuomilehto</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Tsuang</surname>, <given-names>M. T.</given-names></string-name>, <string-name><surname>Watkins</surname>, <given-names>H. C.</given-names></string-name>, <string-name><surname>Wilson</surname>, <given-names>J. G.</given-names></string-name>, <string-name><surname>Daly</surname>, <given-names>M. J.</given-names></string-name>, <string-name><surname>MacArthur</surname>, <given-names>D. G.</given-names></string-name>, and <string-name><given-names>Exome</given-names> <surname>Aggregation</surname></string-name>, C. (<year>2016</year>) <article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source>Nature</source> <volume>536</volume>, <fpage>285</fpage>&#x2013;<lpage>291</lpage></mixed-citation></ref>
<ref id="c13"><label>[13]</label><mixed-citation publication-type="journal"><string-name><surname>Schymkowitz</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Borg</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Stricher</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Nys</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Rousseau</surname>, <given-names>F.</given-names></string-name>, and <string-name><surname>Serrano</surname>, <given-names>L.</given-names></string-name> (<year>2005</year>) <article-title>The FoldX web server: an online force field</article-title>. <source>Nucleic Acids Res</source> <volume>33</volume>, <fpage>W382</fpage>&#x2013;<lpage>388</lpage></mixed-citation></ref>
<ref id="c14"><label>[14]</label><mixed-citation publication-type="journal"><string-name><surname>Grunert</surname>, <given-names>S. C.</given-names></string-name>, <string-name><surname>Stucki</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Morscher</surname>, <given-names>R. J.</given-names></string-name>, <string-name><surname>Suormala</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Burer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Burda</surname>, <given-names>p.</given-names></string-name>, <string-name><surname>Christensen</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Ficicioglu</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Herwig</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kolker</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Moslinger</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Pasquini</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Santer</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Schwab</surname>, <given-names>K. O.</given-names></string-name>, <string-name><surname>Wilcken</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Fowler</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Yue</surname>, <given-names>W. W.</given-names></string-name>, and <string-name><surname>Baumgartner</surname>, <given-names>M. R.</given-names></string-name> (<year>2012</year>) <article-title>3-methylcrotonyl-CoA carboxylase deficiency: clinical, biochemical, enzymatic and molecular studies in 88 individuals</article-title>. <source>Orphanet J Rare Dis</source> <volume>7</volume>, <fpage>31</fpage></mixed-citation></ref>
<ref id="c15"><label>[15]</label><mixed-citation publication-type="journal"><string-name><surname>Hamed</surname>, <given-names>R. B.</given-names></string-name>, <string-name><surname>Gomez-Castellanos</surname>, <given-names>J. R.</given-names></string-name>, <string-name><given-names>Sean</given-names> <surname>Froese</surname></string-name>, D., <string-name><surname>Krysztofinska</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Yue</surname>, <given-names>W. W.</given-names></string-name>, and <string-name><surname>Schofield</surname>, <given-names>C. J.</given-names></string-name> (<year>2016</year>) <article-title>Use of Methylmalonyl-CoA Epimerase in Enhancing Crotonase Stereoselectivity</article-title>. <source>Chembiochem</source> <volume>17</volume>, <fpage>471</fpage>&#x2013;<lpage>473</lpage></mixed-citation></ref>
<ref id="c16"><label>[16]</label><mixed-citation publication-type="journal"><string-name><surname>Chaikuad</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Knapp</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>von Delft</surname>, <given-names>F.</given-names></string-name> (<year>2015</year>) <article-title>Defined PEG smears as an alternative approach to enhance the search for crystallization conditions and crystal-quality improvement in reduced screens</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source> <volume>71</volume>, <fpage>1627</fpage>&#x2013;<lpage>1639</lpage></mixed-citation></ref>
<ref id="c17"><label>[17]</label><mixed-citation publication-type="journal"><string-name><surname>McCoy</surname>, <given-names>A. J.</given-names></string-name> (<year>2007</year>) <article-title>Solving structures of protein complexes by molecular replacement with Phaser</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source> <volume>63</volume>, <fpage>32</fpage>&#x2013;<lpage>41</lpage></mixed-citation></ref>
<ref id="c18"><label>[18]</label><mixed-citation publication-type="journal"><string-name><surname>Emsley</surname>, <given-names>p.</given-names></string-name>, <string-name><surname>Lohkamp</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Scott</surname>, <given-names>W. G.</given-names></string-name>, and <string-name><surname>Cowtan</surname>, <given-names>K.</given-names></string-name> (<year>2010</year>) <article-title>Features and development of Coot</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source> <volume>66</volume>, <fpage>486</fpage>&#x2013;<lpage>501</lpage></mixed-citation></ref>
<ref id="c19"><label>[19]</label><mixed-citation publication-type="journal"><string-name><surname>Murshudov</surname>, <given-names>G. N.</given-names></string-name>, <string-name><surname>Vagin</surname>, <given-names>A. A.</given-names></string-name>, and <string-name><surname>Dodson</surname>, <given-names>E. J.</given-names></string-name> (<year>1997</year>) <article-title>Refinement of macromolecular structures by the maximum-likelihood method</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source> <volume>53</volume>, <fpage>240</fpage>&#x2013;<lpage>255</lpage></mixed-citation></ref>
<ref id="c20"><label>[20]</label><mixed-citation publication-type="journal"><string-name><surname>Adams</surname>, <given-names>p. D.</given-names></string-name>, <string-name><surname>Afonine</surname>, <given-names>p. V.</given-names></string-name>, <string-name><surname>Bunkoczi</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>V. B.</given-names></string-name>, <string-name><surname>Davis</surname>, <given-names>I. W.</given-names></string-name>, <string-name><surname>Echols</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Headd</surname>, <given-names>J. J.</given-names></string-name>, <string-name><surname>Hung</surname>, <given-names>L. W.</given-names></string-name>, <string-name><surname>Kapral</surname>, <given-names>G. J.</given-names></string-name>, <string-name><surname>Grosse-Kunstleve</surname>, <given-names>R. W.</given-names></string-name>, <string-name><surname>McCoy</surname>, <given-names>A. J.</given-names></string-name>, <string-name><surname>Moriarty</surname>, <given-names>N. W.</given-names></string-name>, <string-name><surname>Oeffner</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Read</surname>, <given-names>R. J.</given-names></string-name>, <string-name><surname>Richardson</surname>, <given-names>D. C.</given-names></string-name>, <string-name><surname>Richardson</surname>, <given-names>J. S.</given-names></string-name>, <string-name><surname>Terwilliger</surname>, <given-names>T. C.</given-names></string-name>, and <string-name><surname>Zwart</surname>, <given-names>p. H.</given-names></string-name> (<year>2010</year>) <article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source> <volume>66</volume>, <fpage>213</fpage>&#x2013;<lpage>221</lpage></mixed-citation></ref>
<ref id="c21"><label>[21]</label><mixed-citation publication-type="journal"><string-name><surname>Plessl</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Burer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Lutz</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Yue</surname>, <given-names>W. W.</given-names></string-name>, <string-name><surname>Baumgartner</surname>, <given-names>M. R.</given-names></string-name>, and <string-name><surname>Froese</surname>, <given-names>D. S.</given-names></string-name> (<year>2017</year>) <article-title>Protein destabilization and loss of protein-protein interaction are fundamental mechanisms in cblA-type methylmalonic aciduria</article-title>. <source>Hum Mutat</source> <volume>38</volume>, <fpage>988</fpage>&#x2013;<lpage>1001</lpage></mixed-citation></ref>
<ref id="c22"><label>[22]</label><mixed-citation publication-type="journal"><string-name><surname>Forny</surname>, <given-names>p.</given-names></string-name>, <string-name><surname>Froese</surname>, <given-names>D. S.</given-names></string-name>, <string-name><surname>Suormala</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Yue</surname>, <given-names>W. W.</given-names></string-name>, and <string-name><surname>Baumgartner</surname>, <given-names>M. R.</given-names></string-name> (<year>2014</year>) <article-title>Functional characterization and categorization of missense mutations that cause methylmalonyl-CoA mutase (MUT) deficiency</article-title>. <source>Hum Mutat</source> <volume>35</volume>, <fpage>1449</fpage>&#x2013;<lpage>1458</lpage></mixed-citation></ref>
<ref id="c23"><label>[23]</label><mixed-citation publication-type="journal"><string-name><surname>Baumgartner</surname>, <given-names>M. R.</given-names></string-name>, <string-name><surname>Almashanu</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Suormala</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Obie</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Cole</surname>, <given-names>R. N.</given-names></string-name>, <string-name><surname>Packman</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Baumgartner</surname>, <given-names>E. R.</given-names></string-name>, and <string-name><surname>Valle</surname>, <given-names>D.</given-names></string-name> (<year>2001</year>) <article-title>The molecular basis of human 3-methylcrotonyl-CoA carboxylase deficiency</article-title>. <source>J Clin Invest</source> <volume>107</volume>, <fpage>495</fpage>&#x2013;<lpage>504</lpage></mixed-citation></ref>
<ref id="c24"><label>[24]</label><mixed-citation publication-type="journal"><string-name><surname>Suormala</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Baumgartner</surname>, <given-names>M. R.</given-names></string-name>, <string-name><surname>Coelho</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Zavadakova</surname>, <given-names>p.</given-names></string-name>, <string-name><surname>Kozich</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Koch</surname>, <given-names>H. G.</given-names></string-name>, <string-name><surname>Berghauser</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wraith</surname>, <given-names>J. E.</given-names></string-name>, <string-name><surname>Burlina</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sewell</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Herwig</surname>, <given-names>J.</given-names></string-name>, and <string-name><surname>Fowler</surname>, <given-names>B.</given-names></string-name> (<year>2004</year>) <article-title>The cblD defect causes either isolated or combined deficiency of methylcobalamin and adenosylcobalamin synthesis</article-title>. <source>J Biol Chem</source> <volume>279</volume>, <fpage>42742</fpage>&#x2013;<lpage>42749</lpage></mixed-citation></ref>
</ref-list>
</back>
</article>